Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx
1. Eli Lilly partners to reduce costs of obesity diabetes drugs. 2. Medicare coverage expansion for GLP-1 treatments starts in mid-2026. 3. Lilly's Zepbound price drops to $299; obesity drug costs $149 post-approval. 4. Successful Phase 2 trial for eloralintide; Phase 3 studies to commence. 5. Lilly receives tariff relief in exchange for price reductions.